Xbrane Biopharma

New England Biolabs introduces Xbrane Bioscience's tunable protein expression system for production of challenging proteins

Pressmeddelande   •   Jan 18, 2010 10:32 CET

New England Biolabs (NEB) has introduced Lemo21(DE3) Competent E. coli, a tunable T7 expression strain optimized for the expression of difficult constructs, including membrane proteins, toxic proteins and proteins prone to insoluble expression. A derivative of BL21(DE3), Lemo21(DE3) offers the host features of this commonly used expression strain, with the added benefit of being able to finely tune T7 expression. Tunable expression is achieved by varying the T7 RNA Polymerase activity to determine the optimal level of expression for each individual target protein.

Lemo21(DE3) is the first commercial product from NEB based on the Lemo System™, a technology developed by Xbrane Bioscience, a company originating from the Center for Biomembrane Research at Stockholm University. NEB and Xbrane Bioscience recently announced an agreement in which NEB would commercialize products based on the Lemo System through its international distribution network. Additionally, the technology is available for licensing by both companies.

Lemo 21(DE3) Competent E. coli is being launched at the Pep Talk 2010 Protein Expression Conference, January 12-15, 2010 in San Diego, CA.

About Xbrane Bioscience
Xbrane Bioscience develops and commercializes versatile platforms for efficient and cost-effective production of proteins and vaccines. The company was founded early 2008, as a spin-off company from the world-leading Center for Biomembrane Research at the Department of Biochemistry & Biophysics of Stockholm University, Sweden. The company has developed the tunable expression system, Lemo System and is now engineering platforms for E. coli that allow both high-yield protein expression on its cell surface and in the extracellular medium. For more information about Xbrane Bioscience visit www.xbranebio.com.

About New England Biolabs Inc.
Established in the mid 1970’s, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genome research. NEB continues to expand its product offerings into areas related to PCR, cloning, expression and purification, and is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.